IDEAYA Biosciences had its Relative Strength (RS) Rating upgraded from 65 to 75 Monday — a welcome improvement, but still below the 80 or higher score you prefer to see.
Can You Really Time The Stock Market?
IBD's proprietary rating tracks share price performance with a 1 (worst) to 99 (best) score. The rating shows how a stock's price performance over the last 52 weeks stacks up against all the other stocks in our database.
Over 100 years of market history reveals that the top-performing stocks typically have an RS Rating of at least 80 as they launch their biggest price moves. See if IDEAYA Biosciences can continue to show renewed price strength and clear that threshold.
IDEAYA Biosciences is now considered extended and out of buy range after clearing a 23.09 buy point in a first-stage flat base. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week moving average.
IDEAYA Biosciences posted 0% earnings growth last quarter. Sales gains came in at 79%.
IDEAYA Biosciences earns the No. 228 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and Rigel Pharmaceuticals are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
